Citations

Mayo Clinic

Showing 10 of 108523 citations.

NK cell signaling to cytotoxicity - parts II & III
Billadeau, Dan

The Biomedical & Life Sciences Collection | July 25, 2024 | Volume: 2010 | Issue: 10 | Pages: e1002835

10.69645/cylp8916 Get It

When is it useful to genotype Parkinson's disease patients?
Wszolek, Zbigniew, Wszołek, Zbigniew K.

The Biomedical & Life Sciences Collection | July 25, 2024 | Volume: 2023 | Issue: 5 | Pages: e1006034

10.69645/aroz5348 Get It

Enhancing neuro-oncology care through equity-driven applications of artificial intelligence
Mehari, Mulki , Sibih, Youssef , Dada, Abraham , Chang, Susan M. , Wen, Patrick Y. , Molinaro, Annette M. , Chukwueke, Ugonma , Budhu, Joshua , Jackson, Sadhana , Porter, Alyx B. , Hervey‐Jumper, Shawn L. , Budhu, Joshua A , Porter, Alyx , Hervey-Jumper, Shawn L , Jackson, Sadhana , Wen, Patrick Yung , Molinaro, Annette M. , McFaline-Figueroa, J Ricardo

Neuro-Oncology | July 25, 2024 | Volume: 26 | Issue: 11 | Pages: 1951-1963

10.1093/neuonc/noae127 | PMID 39159285 Get It

Abstract The disease course and clinical outcome for brain tumor patients depend not only on the molecular and histological features of the tumor but also on the patient’s demographics and social determinants of health. While current investigations in neuro-oncology have broadly utilized artificial intelligence (AI) to enrich tumor diagnosis and more accurately predict treatment response, postoperative complications, and survival, equity-driven applications of AI have been limited. However, AI applications to advance health equity in the broader medical field have the potential to serve as practical blueprints to address known disparities in neuro-oncologic care. In this consensus review, we will describe current applications of AI in neuro-oncology, postulate viable AI solutions for the most pressing inequities in neuro-oncology based on broader literature, propose a framework for the effective integration of equity into AI-based neuro-oncology research, and close with the limitations of AI.
Impact of Dementia in Colorectal Cancer Patients: United States Population-Based Cohort Study
Suenghataiphorn, Thanathip , Danpanichkul, Pojsakorn , Saowapa, Sakditad , Thongpiya, Jerapas , Suenghataiphorn, Thanathip , Danpanichkul, Pojsakorn , Kulthamrongsri, Narathorn , Polpichai, Natchaya

The Korean Journal of Gastroenterology | July 25, 2024 | Volume: 84 | Issue: 1 | Pages: 17-23

10.4166/kjg.2024.057 | PMID 39049461 Get It

Clarification of our response to “The importance of diversity in Obesity articles”
Clark, Matthew M. , Wadden, Thomas A. , Redman, Leanne M. , Jensen, Michael D. , Wadden, Thomas A , Redman, Leanne , Jensen, Michael , Cardel, Michelle I.

Obesity | July 25, 2024 | Volume: 32 | Issue: 9 | Pages: 1607-1608

10.1002/oby.24112 | PMID 39049195 Get It

Biocompatible Liquid Embolic for the Treatment of Microvascular Hemorrhage
Keum, Hyeongseop , Zhang, Zefu , Albadawi, Hassan , Öklü, Rahmi , Kim, Jinjoo , Graf, Erin, Oklu, Rahmi , Graf, Erin H.

Advanced Science | July 25, 2024 | Volume: 11 | Issue: 34 | Pages: No page available

10.1002/advs.202403615 | PMID 39049735 Get It

AbstractPersistent or recurrent bleeding from microvessels inaccessible for direct endovascular intervention is a major problem in medicine today. Here, an innovative catheter‐directed liquid embolic (P‐LE) is bioengineered for rapid microvessel embolization to treat small vessel hemorrhage. Tested in rodent, porcine, and canine animal models under normal and coagulopathic conditions, P‐LE outperformed clinically used embolic materials in both survival and non‐survival experiments, effectively occluding vessels as small as 40 microns with no signs of recanalization. P‐LE occlusion is independent of the coagulation cascade, and its resistance to displacement is ≈ 8 times greater than systolic blood pressure. P‐LE is also found to be biocompatible and x‐ray visible and does not require polymerization or a chemical reaction to embolize. To simulate the clinical scenario, acute microvascular hemorrhage is created in the pig kidney, liver, or stomach; these are successfully treated with P‐LE achieving immediate hemostasis. Furthermore, P‐LE is found to be bactericidal to highly resistant patient‐derived bacteria, suggesting that P‐LE may also protect against infectious complications that may occur following embolization procedures. P‐LE is safe, easy to use, and effective in treating ‐microvessel hemorrhage.
Pulmonary complications of advanced chronic liver diseases: an updated review
Thévenot, Thierry , Raevens, Sarah , Aujayeb, Avinash , Banini, Bubu A. , Cadranel, J.F. , DuBrock, Hilary M. , DuBrock, Hilary M , Aujayeb, Avinash

Exploration of Digestive Diseases | July 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: 301-325

10.37349/edd.2024.00053 Get It

Patients with advanced chronic liver disease can develop specific pulmonary complications related or unrelated to pre-existing lung disease. The three major pulmonary complications in this patient population include hepatopulmonary syndrome (HPS), portopulmonary hypertension (PoPH), and hepatic hydrothorax (HH). These entities are most often revealed by increasing dyspnea together with signs of portal hypertension. The prevalence of these complications remains underestimated due to the lack of routine screening of the cirrhotic population. The pathophysiology of HH is better understood than that of HPS and PoPH. The clinical features, diagnosis, and therapeutic options of these pulmonary complications are extensively discussed in this chapter. Liver transplantation may offer a curative therapy in highly-selected cases and MELD exception points allow priority access to liver transplantation, thus avoiding potential deterioration while awaiting transplant and providing a better post liver transplant survival. The complexity of managing these pulmonary complications requires a multidisciplinary team approach, especially when liver transplantation is indicated.
Vascular Postoperative Changes After Facial Flap Repairs: An Opportunity for Early Intervention
Berman, Hannah S. , Awe, Olufolakemi, White, Launia J. , Carrasquillo, Osward Y. , Barbosa, Naiara S. , Merritt, Bradley G., Degesys, Catherine A. , Barbosa, Naiara, Heckman, Michael G.

Dermatologic Surgery | July 25, 2024 | Volume: 51 | Issue: 1 | Pages: 5-10

10.1097/dss.0000000000004352 | PMID 39048093 Get It

BACKGROUND Flap repair provides unique advantages in facial reconstruction but still carries the potential for undesirable postoperative cosmetic changes. OBJECTIVE The aims of this study were to describe postoperative vascular outcomes of patients undergoing flap repairs after Mohs micrographic surgery on facial tumors and to assess associations of baseline characteristics with outcomes. MATERIALS AND METHODS In this study, 7 dermatologists and 1 physician assistant in dermatology assessed preoperative and postoperative photographs of 57 patients who underwent facial Mohs micrographic surgery, evaluating vascular and pigment outcomes and number of telangiectasias. RESULTS There was a significant difference in number of telangiectasias according to body location (p = .002), where the number of telangiectasias was highest for nose surgery. CONCLUSION These data suggest that nasal flap repairs are associated with increased postoperative vascular changes. This highlights an opportunity for improved preoperative patient counseling and possible early laser treatment after nasal Mohs micrographic surgery.
Esophageal cancer mortality disparities between Black and White adults in the United States, 1999–2020: insights from CDC‐WONDER
Pan, Chun‐Wei , Wang, Yichen , Abboud, Yazan , Dominguez, Alejandro Nieto , Pang, Maoyin , Pang, Maoyin , Wang, Yichen , Lo, Chun‐Han

Journal of Gastroenterology and Hepatology | July 24, 2024 | Volume: 39 | Issue: 11 | Pages: 2340-2350

10.1111/jgh.16689 | PMID 39048101 Get It

AbstractBackground and AimEsophageal cancer significantly contributes to US cancer mortality, with notable racial disparities. This study aims to provide updated esophageal cancer mortality trends among Black and White adults from 1999 to 2020.MethodsCDC‐WONDER was used to identify Black and White adults in the United States from 1999 to 2020. We calculated age‐standardized mortality rates, absolute rate differences, and rate ratios to compare the mortality differences between these populations.ResultsFrom 1999 to 2020 in the United States, there were 303 267 esophageal cancer deaths, with significant racial disparities. The age‐adjusted mortality rate for Black adults fell from 6.52 to 2.62 per 100 000, while for White adults, it declined from 4.19 to 3.97 per 100 000, narrowing the racial mortality gap. Gender‐wise, the study showed a decrease in the mortality rate from 3.31 to 2.29 per 100 000 in Black women, but an increase from 1.52 to 1.99 per 100 000 in White women. Among young men, the rate dropped in Black men from 12.82 to 6.26 per 100 000 but rose in White men from 9.90 to 10.57 per 100 000. Regionally, Black adults in the Midwest and South initially had higher mortality rates than Whites, but this gap reduced over time. By 2020, Black men had lower mortality rates across all regions.ConclusionsOver the last two decades, age‐adjusted esophageal cancer mortality decreased in Black adults but stabilized in White adults, reflecting distinct cancer trends and risk factors. The study highlights the importance of tailored public health strategies for healthcare access and risk factor management.
Using Electronic Health Record Mortality Data to Promote Goals-of-Care Discussions in Seriously Ill Transferred Patients: A Pilot Study
Mahendraker, Neetu , Gutierrez-Asis, Esmeralda , Williams, Linda S. , Park, Seho , Schleyer, Titus , Umberfield, Elizabeth E.

ACI Open | July 24, 2024 | Volume: 08 | Issue: 02 | Pages: e69-e78

10.1055/s-0044-1788652 | PMID 42523226 Get It

Abstract Background Mortality prediction data may aid in identifying seriously ill transferred patients at high risk of dying and facilitate early goals-of-care discussions (GOCD); however, this is rarely evaluated. We recently developed a model for predicting 30-day inpatient mortality, which may be useful for promoting early GOCD. Objectives Our objectives were to examine the effects of sharing model-generated mortality risk with hospitalists by assessing (1) if hospitalists agreed with the mortality risk prediction, (2) if they planned to conduct GOCD or consult palliative care within 72 hours of transfer, and (3) if the communication alert affected GOCD timing and other clinical outcomes. We also aimed to measure the association between both the model-generated and hospitalists' stratified risk assessments with patient mortality. Methods This was a nonrandomized quasi-experimental pilot study with a historical control group. On the second day of hospitalization, the model-generated risk was communicated to the hospitalists. Hospitalists were asked to answer questions via a HIPAA (Health Insurance Portability and Accountability Act)-compliant mobile communication system, and clinical outcomes were extracted via chart review. Results Eighty-four patients (42 in the control and 42 in the intervention group) were included in this study. Hospitalists agreed that all patients in the intervention group were at risk for inpatient mortality. Hospitalists were more likely to indicate a plan to conduct GOCD in the intervention group (n = 9) compared with the control group (n = 4, p < 0.001). In this subset of patients, GOCD was completed within 72 hours in 78% of intervention patients (n = 7) as compared with 50% in the control group (n = 2). The greater absolute value of the model-generated mortality risk was significantly associated with deaths (p = 0.01), similar to the hospitalists' prediction of the mortality risk (p = 0.02). Conclusion Communicating model-generated mortality risk to hospitalists is a promising approach to promote timely GOCD.